ALK-Abell車
is the world-leading producer of pharmaceuticals for specific allergy
vaccination. As opposed to traditional symptom relieving medication,
allergy vaccination not only treats the allergic symptoms, but also the
underlying immunological causes of allergy. ALK-Abell車 is determined to
improve the allergy treatment offered to patients and physicians by
developing new tablet-based and recombinant allergy vaccines.
ALK-Abell車
is an international group comprising more than 1000 employees
with subsidiaries and associated companies in Austria, China, Denmark,
Finland, Germany, Italy, the Netherlands, Norway, Spain, Sweden, the
United Kingdom and the USA. The company is represented by distributors in
Asia, Africa and Australia. The headquarters and primary research
facilities are situated in Hørsholm, north of the Danish capital of
Copenhagen.
Vision
"We want to cure allergy and to fundamentally transform allergy
treatment through the continuous development of more effective and patient
friendly products".
Mission
"We improve the health and quality of life for people with allergies
around the world by providing the best products and services".
ALK-Abell車's
product portfolio covers all aspects of allergy from diagnosis to
treatment. The core business is allergy vaccination, which unlike
symptomatic treatment is capable treating the underlying immunological
cause of the allergic disease.
Allergy
vaccination, or immunotherapy, is a treatment based on controlled
doses of standardized natural allergens administered as subcutaneous
injections (under the skin) or sublingual drops (under the tongue).
During the treatment, the immune system is gradually desensitized, so that
the patient gets accustomed to the allergens that normally cause an
allergic reaction.
﹛ |
